New intelligence capabilities empower companies to deliver cutting-edge medical innovations to the right patients faster

AcuityMD, the AI platform for MedTech, announced today at its annual Flywheel event for commercial leaders a major expansion of its platform with new AI tools to give medical device companies visibility into forecasted sales performance, business risks, and next-best actions to reach their goals. AcuityMD is modernizing how MedTech companies go to market by applying AI to improve efficiency and effectiveness – ultimately accelerating the delivery of life-changing medical innovations to patients.

In today’s competitive market, MedTech commercial teams face constant pressure to hit sales targets, but fragmented tools and incomplete data make it hard to forecast accurately and prioritize the right opportunities. AcuityMD solves this by delivering reliable forecasts and AI-driven action plans that help leaders focus resources, guide reps to the best opportunities, and accelerate revenue growth.

Built on AcuityMD’s foundation of real-world market data and advanced targeting technology, the new AI enhancements add a powerful layer of insights plus guided execution that continuously adapt and improve over time. With AcuityMD, MedTech companies can now:

• Hit quotas faster with generative next-best actions – sales representatives are automatically guided to the highest-value opportunities with the strongest likelihood of success. The AI recommendation engine continuously learns from interactions to deliver smarter, more personalized guidance over time.
• Plan with precision with MedTech-specific forecasting – leaders can make better strategic decisions by combining sales data, run-rate business projections, and weighted pipeline data into a single, reliable forecast that is purpose-built for MedTech.
• Unlock field intelligence with an AI voice assistant – convert sales representatives’ observations into structured insights, cutting manual data entry and ensuring timely and accurate field information.

“Most forecasting tools stop at projecting outcomes,” said Brian Collins, Chief Product Officer at AcuityMD. “Our platform goes further by showing teams how to achieve outcomes. Together with our customers, we’re applying AI to bring clarity, focus, and faster adoption of medical technology.”

Corza Biosurgery Area Sales Director Pat O’Brien added, “Our sales data was spread across multiple platforms, which created a significant administrative burden and made it difficult for leadership to track performance to quota.” Fellow Area Sales Director Kara Dillon concluded, “AcuityMD has given us the ability to instantly assess sales performance, support our reps where needed, and create more accurate quotas based on real data.”

Both Pat O’Brien and Kara Dillon are speaking at AcuityMD’s Flywheel 2025 in Chicago today.

Learn more at www.acuitymd.com or schedule a demo here.

About AcuityMD

AcuityMD is the AI platform for MedTech and trusted by more than 400 MedTech companies – including six of the top 10. Commercial leaders use AcuityMD to identify target markets, surface top opportunities, and grow their business. By combining real-world market data with AI-powered insights, AcuityMD enables companies from pre-commercial to enterprise to understand where and how to sell faster to accelerate the adoption of medical technology. AcuityMD was named to Forbes’ 2025 “Next Billion-Dollar Startups” list – an elite group of 25 venture-backed U.S. companies identified as most likely to reach a $1 billion valuation.Learn more at www.acuitymd.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20251007545689/en/

AcuityMD is modernizing how MedTech companies go to market by applying AI to improve efficiency and effectiveness – ultimately accelerating the delivery of life-changing medical innovations to patients.